TKT May Have Enablement Argument Vs. Amgen's EPO Patents, Judge Says
Executive Summary
Transkaryotic Therapies may have an enablement argument against Amgen's patents for erythropoietin, Judge William Young said during a hearing held March 27-28 in Boston federal court to define claims included in the EPO marketer's patents.
You may also be interested in...
TKT Asks Judge To Limit Amgen's "30 Years" EPO Exclusivity As Trial Begins
Amgen's erythropoietin patents should not translate into 30 years of Epogen exclusivity, Transkaryotic Therapies said in opening arguments May 15 in Boston federal court.
TKT Asks Judge To Limit Amgen's "30 Years" EPO Exclusivity As Trial Begins
Amgen's erythropoietin patents should not translate into 30 years of Epogen exclusivity, Transkaryotic Therapies said in opening arguments May 15 in Boston federal court.
Amgen/TKT EPO
Trial set for May 15 in EPO patent dispute. Amgen claims TKT's gene-activated erythropoietin infringes its Epogen patents (1"The Pink Sheet" April 3, p. 7). Judge William Young will hear the case in Boston federal court